Search
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archived checkbox.
Displaying 1 - 10 of 10 items.
0.9% Sodium Chloride Injection USP: Leaking solution bag
Solution bags may be leaking in affected lot.
RecallHealth product recall | 2022-02-28
Distribution of NUVAXOVID with English-only Vial and Carton Labels
NUVAXOVID was authorized by Health Canada on February 17, 2022. In order to provide earlier access to NUVAXOVID in the context of the global pandemic, Novavax, Inc. will distribute product vials, cartons and package inserts that are in English only for a…
AlertHealth professional risk communication | 2022-02-23
Rapid Protectant Hand Sanitizer Gel: labelling
Affected lot(s) may be missing risk statements and the non medicinal ingredient carbomer on the outer label.
RecallHealth product recall | 2022-02-23
Octagam 10% (Immune globulin intravenous, Human):Quality issue
Elevated reporting rate of hypersensitivity reactions in affected lot.
RecallHealth product recall | 2022-02-23
Odan Itraconazole: Out of specification
The assay is out of specification in the affected lot
RecallHealth product recall | 2022-02-23
The Newfoundland Distillery Company - Fighting Spirit: Acetaldehyde outside acceptable limit
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
Alcohol Antiseptic 80% (v/v) Topical Solution Hand Sanitizer: Acetaldehyde outside acceptable limit
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
Auralgan: Impurities out of specification
Impurities could be out of specification in affected lots.
RecallHealth product recall | 2022-02-04
Vitastack: missing risk statement
Affected lot is missing risk statements on the outer label.
RecallHealth product recall | 2022-02-04
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
An increased incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and retinal vascular occlusion (RO), was observed in patients who received BEOVU 6 mg with every 4 weeks (q4 week) dosing beyond the first 3 doses compared to…
AlertHealth professional risk communication | 2022-02-03